Vidulich Kelley A, Talpur Rakhshandra, Bassett Roland L, Duvic Madeleine
Department of Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77027, USA.
Int J Dermatol. 2009 Mar;48(3):243-52. doi: 10.1111/j.1365-4632.2009.03771.x.
The most common cutaneous T-cell lymphomas (CTCLs) are mycosis fungoides and Sézary syndrome.
To determine whether blood stage and other prognostic variables affect overall survival (OS) in CTCL.
We studied retrospectively 1197 CTCL patients seen at the M.D. Anderson Cancer Center since 1987.
We identified 124 (10.3%) patients with erythrodermic CTCL (E-CTCL), 63% of whom had positive gene rearrangements in skin and 19 of whom had no evidence of hematologic involvement. The median age at diagnosis was 63 years (range, 26-90 years); the male to female ratio was 1.3 : 1. OS curves were estimated by the Kaplan-Meier method and compared using log-rank tests. The median OS in all 124 E-CTCL patients was 5.1 years (range, 0.4-18.6 years) regardless of the cause of death or blood involvement. Patients were stratified by the H0-H4 staging system with manual or flow cytometric determination of Sézary cell counts (Russell-Jones R, Whittaker SJ. Sézary syndrome: diagnostic criteria and therapeutic options. Semin Cutan Med Surg 2000; 19: 100-108). The median OS was 7.6 years for H0-H2 (< 1000 Sézary cells/L) (n = 23), 5.4 years for H3 (>or= 1000 to <or= 10,000 Sézary cells/L) (n = 79), and 2.4 years for H4 (>or= 10,000 Sézary cells/L) (n = 22) (P = 0.011). Treatment with systemic steroids, age, serum lactate dehydrogenase, and white blood cell count >or= 20,000 microL were significant prognostic factors, but large cell transformation, T-cell receptor gene rearrangement, tumor-node-metastasis stage, treatments, and CD4 : CD8 ratio were not. In multivariate analysis, advanced age and elevated lactate dehydrogenase were the strongest predictors of a poor prognosis.
Serum LDH and age were the strongest predictive factors for OS in E-CTCL.
最常见的皮肤T细胞淋巴瘤(CTCL)是蕈样肉芽肿和 Sézary 综合征。
确定血液分期和其他预后变量是否影响 CTCL 患者的总生存期(OS)。
我们回顾性研究了自1987年以来在 MD 安德森癌症中心就诊的1197例 CTCL 患者。
我们确定了124例(10.3%)红皮病型 CTCL(E-CTCL)患者,其中63%的患者皮肤基因重排呈阳性,19例患者无血液系统受累证据。诊断时的中位年龄为63岁(范围26 - 90岁);男女比例为1.3 : 1。采用 Kaplan-Meier 法估计 OS 曲线,并使用对数秩检验进行比较。无论死亡原因或血液受累情况如何,所有124例 E-CTCL 患者的中位 OS 为5.1年(范围0.4 - 18.6年)。根据 H0 - H4 分期系统对患者进行分层,通过手工或流式细胞术测定 Sézary 细胞计数(Russell-Jones R, Whittaker SJ. Sézary 综合征:诊断标准和治疗选择。皮肤医学与外科学杂志2000;19:100 - 108)。H0 - H2(Sézary 细胞<1000个/升)患者的中位 OS 为7.6年(n = 23),H3(Sézary 细胞≥1000至≤10,000个/升)患者为5.4年(n = 79),H4(Sézary 细胞≥10,000个/升)患者为2.4年(n = 22)(P = 0.011)。全身用类固醇治疗、年龄、血清乳酸脱氢酶以及白细胞计数≥20,000/微升是显著的预后因素,但大细胞转化、T 细胞受体基因重排、肿瘤-淋巴结-转移分期、治疗以及 CD4 : CD8 比值不是。在多变量分析中,高龄和乳酸脱氢酶升高是预后不良的最强预测因素。
血清 LDH 和年龄是 E-CTCL 患者 OS 的最强预测因素。